Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Macugen · 1 trial · 1 indication
Refraction and best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts
| Arm | Type | Description |
|---|---|---|
| Sham Control | SHAM_COMPARATOR | - |
| Macugen | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Standard of Care | DRUG | Clinicians decision to use optional laser therapy. |
| Macugen | DRUG | Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years. |
Inclusion Criteria: * macular edema associated with diabetes * visual acuity between 20/50 and 20/200 Exclusion Criteria: * recent laser therapy in the eye * recent signs of uncontrolled diabetes * blood pressure worse than 160/100 * severe cardiac disease
Macugen is an investigational small molecule being studied for the treatment of Macular Edema Associated With Diabetes Mellitus. It is injected into the eye and is being evaluated for its safety and efficacy in reducing macular swelling associated with diabetes. The drug is currently in Phase 2 clinical development.
Macugen is a small molecule designed for intravitreal injection to treat Macular Edema Associated With Diabetes Mellitus. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being studied for its ability to address macular swelling in diabetic patients.
Macugen is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy for Macular Edema Associated With Diabetes Mellitus. Pfizer is responsible for the ongoing development of this investigational therapy.
Macugen is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of Macular Edema Associated With Diabetes Mellitus, with one completed Phase 2 trial involving 317 participants.
Macugen has one completed clinical trial, NCT00605280, a Phase 2 study evaluating the safety and efficacy of pegaptanib sodium (Macugen) injected into the eye every 6 weeks for up to 2 years for macular swelling associated with diabetes. The trial enrolled 317 participants across multiple countries.
Yes, Macugen is also known as pegaptanib sodium. The clinical trial NCT00605280 explicitly refers to pegaptanib sodium (Macugen) as the study drug. This alternative name is used in the trial title and is important for identifying the drug in medical literature and regulatory documents.